FDA
-
-
-
-
-
-
-
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
-
-
-
-
-
-
-
AbCellera (ABCL) -Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
-
-
-
-
-
-
-
Pre-Open Stock Movers 09/17: (CRVS) (ABCL) (BGNE) Higher; (PTGX) (GRTS) (X) Lower (more...)
-
-
-
-
-
-
-
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada
-
-
-
-
-
-
-
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
-
-
-
-
-
-
-
AbCellera (ABCL) -Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
-
-
-
-
-
329,957 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

